Drug Trial Radar · NCT07610005
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Immunome, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.
Conditions
- Healthy
Interventions
Varegacestat Reference FormulationDrug
Oral administration
Varegacestat Test Formulation ADrug
Oral administration
Varegacestat Test Formulation BDrug
Oral administration
Varegacestat Test Formulation CDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the rBA of varegacestat by AUC0-tTime frame: Approximately 3 weeks
- Evaluate the rBA of varegacestat by AUC0-infTime frame: Approximately 3 weeks
- Evaluate the rBA of varegacestat by CmaxTime frame: Approximately 3 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc.
Tempe, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.